Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-17-001767
Filing Date
2017-02-06
Accepted
2017-02-06 15:08:56
Documents
45
Period of Report
2016-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q avir20161231_10q.htm 10-Q 625857
2 EXHIBIT 31.1 ex31-1.htm EX-31.1 16524
3 EXHIBIT 31.2 ex31-2.htm EX-31.2 16484
4 EXHIBIT 32.1 ex32-1.htm EX-32.1 9279
  Complete submission text file 0001437749-17-001767.txt   2785169

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT avir-20161231.xml EX-101.INS 542159
6 XBRL TAXONOMY EXTENSION SCHEMA avir-20161231.xsd EX-101.SCH 31022
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE avir-20161231_cal.xml EX-101.CAL 27621
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE avir-20161231_def.xml EX-101.DEF 178054
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE avir-20161231_lab.xml EX-101.LAB 151741
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avir-20161231_pre.xml EX-101.PRE 194713
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Filer) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-35285 | Film No.: 17575365
SIC: 2836 Biological Products, (No Diagnostic Substances)